Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival 2020 - Electronics

| More

Visaka Industries - Demand and pricing tailwinds sustain; maintain a compelling BUY - ICICI Securities

Posted On: 2020-09-28 22:43:36

Visaka Industries (VSKI) is likely to witness one of the most profitable fiscals (FY21) in the past decade despite the current pandemic. Our channel checks across regions indicate: 1) demand and pricing for VSKI's ACS (rural-centric product) remains defiant despite Q2FY21 being a seasonally lean quarter; 2) Vnext (urban-centric product) demand too has recovered sharply post-Jun'20 amid firm pricing; and 3) sales have recovered 95-100% in Q2FY21 in both ACS and FCB segments. We expect the sustained growth momentum and firm pricing environment to drive sharp improvement in the company's profitability in FY21E. Stricter working capital management and strong FCF generation is likely to help substantial paring of debt resulting in improvement in RoCEs as well. At current valuation of 6.9x FY22E earnings, VSKI remains a compelling BUY.

- Valuation and outlook. Considering the better than expected performance in a seasonally weak quarter (Q2FY21), we increase our revenue/PAT estimates by 2.3%/2.0% and 15.6%/7.8% for FY21E/FY22E respectively. We now expect VSKI to report overall revenue and PAT CAGRs of 6.3% and 27.2%, respectively over FY20-FY22E. Higher profitability and stricter working capital discipline leading to sizeable paring of debt would aid the company in improving its RoCEs to ~15%. Maintain BUY with a revised target price of Rs552 (earlier: Rs512), at 12x FY22E earnings.

- ACS segment continues its growth momentum. After reporting a volume/revenue growth of -14.2%/-0.4% in Q1FY21 in the ACS segment, demand has sustained in the seasonally weak Q2FY21 driven by firm sales in rural India amid higher farm income and good monsoon. While ACS realisations have declined by 4-5% QoQ iin Q2FY21, pricing in the segment remains substantially higher YoY. We thus expect VSKI to report healthy 8.2% / 76% growth in segmental revenue / EBITDA in FY21E.

- Vnext making a strong comeback. Vnext demand, largely urban-centric, has also recovered sharply after witnessing two months of lull (Apr-May'20). Release of the pent-up demand in the segment is in tandem with firm pricing as per our channel checks. With VSKI now planning to put up another greenfield unit in Tamil Nadu to capitalise on the growing demand for Vnext and further consolidate its market share, we expect volumes in the segment to sustain their growth momentum. We also expect segmental EBIDTA margins to witness structural improvement (led by logistical savings) and move into the much-anticipated 12-15% range over the next 2-3 quarters.

- Balance sheet strengthening to aid rerating. Despite (likely) South India capex, improved FCF generation over FY20-FY22E would help VSKI retire sizeable debt and thus improve its overall RoCEs to ~15% levels by FY22E. With earnings growth momentum poised to sustain and balance sheet strengthening likely to continue, we expect the stock to witness rerating in the near term.

Shares of VISAKA INDUSTRIES LTD. was last trading in BSE at Rs.316 as compared to the previous close of Rs. 294.35. The total number of shares traded during the day was 6727 in over 458 trades.

The stock hit an intraday high of Rs. 316.7 and intraday low of 300.75. The net turnover during the day was Rs. 2097207.

Source: Equity Bulls

Click here to send ur comments or to

Amazon Great Indian Festival 2020 - Mobiles

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Reiterate ADD on Amara Raja Batteries - Pent-up demand leads to healthy 2Q - HDFC Securities

Maintain REDUCE on Titan - Reasonable print - HDFC Securities

REDUCE on RBL Bank - Some positives, but key concerns remain - HDFC Securities

Maintain REDUCE on Marico - Saffola shines with PCNO recovery, muted margin - HDFC Securities

Maintain ADD on Dr. Reddy's Labs - Good quarter, lower SG&A cost is encouraging - HDFC Securities

Piramal Enterprises - Acquisition of stake from JV partner - Angel Broking

Maintain BUY on Axis Bank - Provision buffers strengthened (further) - HDFC Securities

AU Small Finance Bank - Q2FY21 Result - Angel Broking

L&T - Q2FY21 - Angel Broking

RBL Bank - Q2FY21 Result - Angel Broking

Axis Bank - Q2FY21 Result - Angel Broking

Marico Ltd - Q2FY21 Result Update - YES Securities

Titan Company Ltd - Q2FY21 Result Update - YES Securities

Axis Bank Limited - Q2FY21 Result Update - YES Securities

RBL Bank Limited - Q2FY21 Result Update - YES Securities

Multi Commodity Exchange of India - Operating leverage aids strong EBITDA performance - ICICI Securities

Titan Company - Faster-than-expected recovery - ICICI Securities

Marico - Strong performance across portfolio - ICICI Securities

Heritage Foods - Lower procurement prices leading to highest EBITDA margin in past decade - ICICI Securities

Axis Bank - Strong core again utilised to create provisioning buffer - ICICI Securities

Supreme Industries - Beat on all counts - ICICI Securities

GSK Pharmaceuticals - Recovery from COVID-19 impact - ICICI Securities

Hero MotoCorp - Solid demand recovery expectations priced in - ICICI Securities

Cement - Demand / prices improve further in Oct'20 - ICICI Securities

CEAT - Replacement demand drives outperformance - ICICI Securities

Dr. Reddy's Laboratories - Outperformance continues - ICICI Securities

ICICI Prudential Life Insurance - VNB trajectory in-line despite YoY dip in protection in Q2 - ICICI Securities

Bharti Airtel - Q2FY21 Result Update - ICICI Securities

Marico - Q2FY21 Result Update - ICICI Securities

Larsen & Toubro - Q2FY21 First Cut - ICICI Securities

Sanofi India - Q3CY20 Company Update - ICICI Securities

Adani Ports and SEZ - Quant Pick - ICICI Securities

Nippon Life India AMC - Q2FY21 Result Update - ICICI Securities

Tata Motors - Q2FY21 Result Update - ICICI Securities

Derivatives Strategy - Mahanagar Gas - Positional Future - ICICI Securities

Supreme Industries - Q2FY21 First Cut - ICICI Securities

Dr Reddy's Laboratories - Q2FY21 First Cut - ICICI Securities

Marico Ltd - Q2FY21 First Cut - ICICI Securities

Apcotex Industries - Q2FY21 First Cut - ICICI Securities

V-Guard Industries - Q2FY21 First Cut - ICICI Securities

Titan Company - Q2FY21 First Cut - ICICI Securities

Navin Fluorine - Q2FY21 First Cut - ICICI Securities

PI Industries - Q2FY21 First Cut - ICICI Securities

L&T - Q2FY21 Earnings First Cut: Beat on EBITDA margins - YES Securities

Bharti Airtel - Q2FY21 result - Angel Broking

Dr.Reddy's Lab - Q2FY21 - Angel Broking

BUY on Mahindra & Mahindra Financial Services - Remains an inexpensive rural play - HDFC Securities

Radico Khaitan - Q2FY21 - Angel Broking

Maintain BUY on CDSL - Firing on all cylinders - HDFC Securities

REDUCE on Nippon Life India Asset Management - Market share stabilising - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019